Immunotherapy in Patient With Poor General Condition
NCT04108026
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Non-small Cell Lung Cancer Stage IV
Interventions
DRUG:
Durvalumab
Sponsor
Intergroupe Francophone de Cancerologie Thoracique